Cost-effectiveness analysis of negative pressure wound therapy dressings after open inguinal vascular surgery - The randomised INVIPS-Trial.


Journal

Journal of tissue viability
ISSN: 0965-206X
Titre abrégé: J Tissue Viability
Pays: England
ID NLM: 9306822

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 12 07 2020
revised: 10 09 2020
accepted: 22 09 2020
pubmed: 14 10 2020
medline: 26 8 2021
entrez: 13 10 2020
Statut: ppublish

Résumé

While the scientific evidence in favour of negative pressure wound therapy (NPWT) dressings on sutured incisions in the prevention of surgical site infections (SSIs) has increased, the cost-effectiveness after vascular surgery has not been evaluated. The aim of this study was to evaluate the cost-effectiveness of NPWT compared to standard dressings for the prevention of SSIs after open inguinal vascular surgery. Patient data were retrieved from the randomised INVIPS-trial's open arm, which included patients randomised to either NPWT or standard dressings. The patients were surveyed for SSIs for 90 days postoperatively. The patients' individual cost data were included and analysed from a healthcare perspective. The patients' quality of life was measured using the Vascuqol-6 questionnaire pre- and 30 days postoperatively. Cost-effectiveness of NPWT was determined by decreased or equal total costs and a significant reduction in SSI incidence. The mean vascular procedure-related costs at 90 days were €16,621 for patients treated with NPWT (n = 59) and €16,285 for patients treated with standard dressings (n = 60), p = 0.85. The SSI incidence in patients treated with NPWT was 11.9% (n = 7/59) compared to 30.0% (n = 18/60) with standard dressings, p = 0.015. This corresponds to an increased mean cost of €1,853 per SSI avoided. The cost-effectiveness plane of incremental vascular procedure-related costs and difference in Vascuqol-6 score showed that 42% of estimates were in the quadrant where NPWT was dominant. NPWT is considered cost-effective over standard dressings in patients undergoing open inguinal vascular surgery due to reduced SSI incidence at no higher costs.

Identifiants

pubmed: 33046345
pii: S0965-206X(20)30120-0
doi: 10.1016/j.jtv.2020.09.005
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Pagination

95-101

Informations de copyright

Copyright © 2020 Tissue Viability Society. Published by Elsevier Ltd. All rights reserved.

Auteurs

Robert Svensson-Björk (R)

Vascular Centre, Skåne University Hospital, Malmö, Sweden; Vascular Diseases Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden. Electronic address: Robert.Svensson_Bjork@med.lu.se.

Sanjib Saha (S)

Health Economics Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden.

Stefan Acosta (S)

Vascular Centre, Skåne University Hospital, Malmö, Sweden; Vascular Diseases Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden.

Ulf-G Gerdtham (UG)

Health Economics Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden; Department of Economics, Lund University, Lund, Sweden.

Julien Hasselmann (J)

Vascular Centre, Skåne University Hospital, Malmö, Sweden; Vascular Diseases Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden.

Giuseppe Asciutto (G)

Vascular Diseases Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden; Department of Vascular and Endovascular Surgery, University Hospital Muenster, Germany.

Moncef Zarrouk (M)

Vascular Centre, Skåne University Hospital, Malmö, Sweden; Vascular Diseases Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH